Humanis has introduced a new treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, making Türkiye the first country after the United States to offer the therapy to patients. The innovative approach, not yet available in European Union countries, aims to address a critical unmet need in neurology and psychiatry.
A New Clinical Option in Parkinson’s Disease Management
Although Parkinson’s disease is widely associated with motor symptoms, some patients may develop psychotic manifestations, including hallucinations and delusions, in the later stages of the disease.
These symptoms can severely impact not only patients’ daily lives but also increase the caregiving burden on family members. As a result, Parkinson’s disease psychosis is considered a clinically complex condition with limited treatment options.
The new therapy introduced by Humanis aims to help address this significant treatment gap.
“Parkinson’s Disease Is Not Only About Motor Symptoms”
Dr. Yalçın Yaşin, Commercial Operations General Manager at Humanis, emphasized that Parkinson’s disease should not be viewed solely through the lens of motor symptoms.
“We know that Parkinson’s disease is not limited to motor symptoms. Psychosis-related symptoms can be extremely challenging for both patients and their families. We are very pleased to introduce a new treatment option in this field to the medical community in Türkiye.”
Yaşin also noted that Humanis closely follows scientific advancements and sees it as a corporate responsibility to bring innovative therapies that provide real benefits to patients to the country.
A Human-Centered Healthcare Approach
Humanis stated that it continues its work with a human-centered healthcare philosophy, focusing not only on treating the disease but also on improving the overall quality of life for patients and their caregivers.
